Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 2/20 | 0.40 |
| ▸ | RXRA | P19793 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | RARB | P10826 | 1/20 | 0.38 |
| ▸ | MYC | P01106 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3591477 | 0.84 | CES2 (0.50) | ALDH1A1MAPTMEN1KMT2ANR1H4 | |
| SCHEMBL28537504 | 0.81 | ALDH1A1 (0.52) | ALDH1A1MAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL12694459 | 0.81 | ALPL (0.41) | ALDH1A1MAPTMEN1KMT2AKCNH2 | |
| SCHEMBL988145 | 0.79 | SMN1; SMN2 (0.48) | ALDH1A1MAPTMEN1KMT2ANR1H4 | |
| Water SCHEMBL3832510 | 0.78 | MYC (0.56) | ALDH1A1MAPTMEN1KMT2ARXRB | |
| SCHEMBL11881710 | 0.78 | MYC (0.56) | ALDH1A1MAPTMEN1KMT2ARXRB | |
| SCHEMBL16056966 | 0.77 | GSK3B (0.55) | ALDH1A1NR1H4RXRBRXRARARB | |
| SCHEMBL28815485 | 0.77 | MTOR (0.40) | ALDH1A1MAPTMEN1KMT2ACES2 | |
| SCHEMBL14918493 | 0.76 | TSHR (0.52) | ALDH1A1CES2CES1 | |
| Water SCHEMBL28751190 | 0.76 | MYC (0.55) | ALDH1A1MAPTMEN1KMT2ARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1257539-B1 | AMINO PYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF OBESITY AND OTHER DISORDERS | ORTHO MCNEIL PHARM INC (US) | 2004-12-29 | — | — | EP | disclosed |
| US-6531478-B2 | For therapy of eating disorder, obesity, bulimia nervosa, diabetes, binge eating, anorexia nervosa, dyslipidimia, hypertension, memory loss, epileptic seizures, migraine, sleep disturbances, pain, sexual/reproductive disorders | KORDIK CHERYL P (US) | 2003-03-11 | — | — | US | disclosed |
| EP-1257539-A2 | AMINO PYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF OBESITY AND OTHER DISORDERS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2002-11-20 | — | — | EP | disclosed |
| US-20020065289-A1 | Amino pyrazole derivatives useful for the treatment of obesity and other disorders | KORDIK CHERYL P (US) | 2002-05-30 | — | — | US | disclosed |
| WO-2001062737-A2 | AMINO PYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF OBESITY AND OTHER DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065289-A1 | Amino pyrazole derivatives useful for the treatment of obesity and other disorders | NPY5R, NPY1R, NPY4R | ALDH1A1 3758/4885MAPT 2451/4885MEN1 2836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.